H.C. Wainwright raised the firm’s price target on TG Therapeutics to $45 from $41 and keeps a Buy rating on the shares. The analyst cites increased Briumvi sales estimates for the target bump. TG’s preliminary Q4 revenue beat estimates, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TGTX:
- TG Therapeutics (NASDAQ:TGTX) Surges after Preliminary Q4 and FY23 Results
- TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
- Precision BioSciences says two deals with TG Therapeutics have $900M potential
- Precision BioSciences to get $47M in near term from TG Therapeutics deal
- TG Therapeutics announces global license agreement with Precision BioSciences
